Table 2.
Characteristics of Cancer Survivor Cohort (N=35)
| Age at Diagnosis (years; median, range) | 7 (0-30) |
| Time Since Therapy Completion (years; median, range) | 10 (5-22) |
| Disease Type | |
| Hematologic Malignancy | 18 (51%) |
| Central Nervous System Tumor | 7 (20%) |
| Other Solid Tumor | 9 (26%) |
| BMT for Non-Malignant Condition | 1 (3%) |
| Radiation | |
| Any Radiation | 18 (51%) |
| Central Nervous System Radiation* | 11 (31%) |
| Abdomen/Pelvis Radiation | 9 (26%) |
| Received Cyclophosphamide Equivalent Dose | |
| Yes | 26 (74%) |
| No | 9 (26%) |
| Total Cyclophosphamide Equivalent Dose (median, range) | 2,500 (0-25,200) |
| Underwent BMT | |
| Allogeneic | 5 (14%) |
| Autologous | 2 (6%) |
| Received Broad Spectrum Antibiotics During Therapy (%) | 23 (66%) |
| Yes | 1 (3%) |
| No | 11 (31%) |
| Unavailable | |
| Total Days of Broad Spectrum Antibiotics (median, range) | 44 (0-190) |
| Measurement (median, range) | |
| Hemoglobin A1c | 4.9% (4.2%-5.8%) |
| Low-Density Lipoprotein (mg/dL) | 81 (26-172) |
| High-Density Lipoprotein (mg/dL) | 48 (32-73) |
| Adiponectin (ng)- Leptin (pg) Ratio | 0.61 (0.07-10.56) |
| Systolic Blood Pressure (mmHg) | 118 (101-138) |
| Diastolic Blood Pressure (mmHg) | 68 (55-83) |
| Body Mass Index (kg/m2) | 23.7 (14.7-32.6) |
Primary Diagnosis include: Acute Lymphoblastic Leukemia (12), Hodgkin Lymphoma (3), Medulloblastoma (2), Osteosarcoma (2) Non-Hodgkin Lymphoma (2) Neuroblastoma (2), Low Grade Glioma (2), Wilms Tumor (2), Acute Myeloid Leukemia (1), Anaplastic Oligoastrocytoma (1), Ewing Sarcoma (1), Langerhans Cell Histiocytosis (1), Mixoid Fibrous Histiocytoma (1), Rhabdomyosarcoma (1), Primitive Neuro-Ectodermal Tumor (1), Other (1).
*
9 patients underwent cranial irradiation, 2 patients underwent (craniospinal irradiation)